证券代码：688139 证券简称：海尔生物 公告编号：2025-059 青岛海尔生物医疗股份有限公司 关于完成补选董事及调整董事会专门委员会委员 的公告 青岛海尔生物医疗股份有限公司董事会 2025 年 11 月 17 日，公司召开第三届董事会第九次会议，审议通过了《关 于调整第三届董事会专门委员会委员的议案》，由于公司董事会成员发生变动， 为保证公司第三届董事会各专门委员会工作顺利开展，根据《公司法》和《公司 章程》的有关规定并结合公司实际情况，对第三届董事会专门委员会成员进行调 整，调整后公司第三届董事会专门委员会组成情况如下： 1、董事会战略与 ESG 委员会：谭丽霞女士（主任委员）、周云杰先生、刘 占杰先生、龚雯雯女士、陈洁女士、胡祥德先生、黄生先生（独立董事）、牛军 先生（独立董事）、许铭先生（独立董事） 2、董事会审计委员会：黄生先生（主任委员，独立董事）、陈洁女士、许 铭先生（独立董事） 3、董事会提名委员会：牛军先生（主任委员，独立董事）、刘占杰先生、 许铭先生（独立董事） 4、董事会薪酬与考核委员会：许铭先生（主任委员，独立董事）、谭丽霞 女士、黄生先生（独立董事） 特此公告。 本公司董事会 ...

青岛海尔生物医疗股份有限公司 关于注销部分回购股份并减少注册资本 暨通知债权人的公告 证券代码：688139 证券简称：海尔生物 公告编号：2025-058 公司债权人可持证明债权债务关系存在的合同、协议及其他凭证的原件及复 印件到公司申报债权。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、通知债权人的原因 青岛海尔生物医疗股份有限公司（以下简称"公司"、"海尔生物"）于 2025 年 10 月 30 日召开了第三届董事会第八次会议，并于 2025 年 11 月 17 日召 开了 2025 年第一次临时股东大会，分别审议通过了《关于变更部分回购股份用 途并注销暨减少注册资本的议案》，同意将存放于公司回购专用证券账户中的 1,459,586 股回购股份的用途进行调整，由"用于员工持股计划或股权激励"调 整为"用于注销并相应减少注册资本"。公司本次变更部分回购股份用途并注销 暨减少注册资本事项是为严格履行公司回购股份方案中关于回购股份使用期限 的相关承诺，同时增强投资者回报能力和水平，切实维护广大投资者利益。注销 完 ...

北京市金杜（青岛）律师事务所 关于青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会 之法律意见书 致：青岛海尔生物医疗股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受青岛海尔生物医疗 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《青岛海尔生物医疗股份有限公司章程》（以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 11 月 17 日召 开的 2025 年第一次临时股东大会（以下简称本次股东大会），并就本次股东大 会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 本所依据上述法律、行政法规、规章、规范性文件和《公司章程》的有关 规定以及本法律意见书出具日以前已经发生或者存在的 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-057 青岛海尔生物医疗股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 本次会议由公司董事会召集，表决方式为现场投票与网络投票相结合的方式。 会议的召集、召开和表决方式符合《中华人民共和国公司法》《上海证券交易所 科创板股票上市规则》和《公司章程》的有关规定。公司董事长谭丽霞女士主持 现场会议。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事8人，出席8人； 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 17 日 （二） 股东大会召开的地点：青岛市高新区丰源路 280 号海尔生物医疗新兴产 业园办公楼 VIP 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 90 | | --- | --- | | 普通股股东人数 | ...

Core Viewpoint - Haier Biomedical announced the election of Liu Zhanjie as the employee representative director on the board, in compliance with the Company Law and the revised articles of association [1] Summary by Relevant Sections - **Board Composition**: The company’s board must include one employee director as per legal requirements [1] - **Election Process**: Liu Zhanjie was elected as the employee representative director through a workers' representative assembly [1] - **Announcement Reference**: Details regarding the board changes were disclosed in the announcement dated October 31 [1]

青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议材料 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议材料 2025 年 11 月 17 日 1 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议材料 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议议程 时间：2025 年 11 月 17 日下午 14:00 召开地点：青岛市高新区丰源路 280 号海尔生物医疗新兴产业园办公楼 VIP 会议室 主持人：董事长 谭丽霞 会议议程： 一、主持人宣布大会开始，参会股东审议各项议案。 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会材料目录 | 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议议程 3 | | --- | | 议案一：关于变更部分回购股份用途并注销暨减少注册资本的议案 6 | | 议案二：关于公司取消监事会、变更注册资本、修订《公司章程》并办理工商变更 | | 登记的议案 7 | | 议案三：关于制定和修订相关公司治理制度的议案 9 | | 议案四：关于补选公司第三届董事会非独立董事的议案 10 | 2 青岛海尔 ...

Core Viewpoint - Haier Biomedical emphasizes the importance of user scenario requirements and is leveraging AI technology to develop intelligent solutions in the medical field [1] Group 1: AI Technology and Solutions - The company is focusing on creating intelligent management solutions for pharmacies and operating rooms, including automated medication dispensing and full-automatic liquid preparation robots [1] - Solutions for operating room behavior management have also been developed [1] Group 2: Targeted Health Management - The company is concentrating on health management for key demographics such as children and the elderly [1] - An AI-driven intelligent appointment scheduling system for vaccination clinics has been established [1]

Core Insights - The article emphasizes that ESG has evolved from an additional requirement to a core competitive necessity for Chinese enterprises, with Haier Biomedical showcasing a model of integrating ESG into sustainable growth through technology-driven practices [1][7] - Haier Biomedical's approach to ESG is rooted in its technological advancements, demonstrating that ESG can be a product of continuous innovation rather than a separate cost center [1][2] Group 1: Technological Innovation and ESG - Haier Biomedical's Eco-Drive technology has improved energy efficiency by 30%, achieving the highest efficiency level globally while maintaining operational stability [2] - The daily energy consumption of a low-temperature refrigerator has decreased from over 20 kWh in 2005 to 4.165 kWh in 2024, marking an 80% reduction over 20 years [2] - The ART intelligent control technology in stability test boxes has achieved an 80% energy savings while maintaining strict temperature control [2][3] Group 2: Economic Benefits and Efficiency - The energy savings from a new ultra-low temperature refrigerator can cover its initial purchase cost within approximately 6.7 years, saving 2.2 million yuan over ten years for a medium-sized sample library [3] - For a large sample library with 400 units, the savings can reach 11.2 million yuan over the same period, demonstrating the economic benefits of energy-efficient technologies [3] Group 3: Comprehensive ESG Integration - Haier Biomedical integrates ESG throughout its entire value chain, from procurement to manufacturing, logistics, and product lifecycle [4][5] - The company promotes "green procurement agreements" with suppliers, emphasizing the use of environmentally friendly materials and local sourcing to reduce carbon emissions [4] - The establishment of a national-level "green factory" and the largest low-temperature cold chain base in the Asia-Pacific region further exemplifies its commitment to reducing operational carbon footprints [4] Group 4: Global Impact and Innovation - Haier Biomedical has developed solar-powered vaccine refrigerators to address storage challenges in regions with inadequate electricity coverage, ensuring vaccine safety even in extreme conditions [6] - The company has expanded its services to over 160 countries, showcasing Chinese innovation in global public health solutions [6] - The launch of the "green ecological co-construction initiative" at the Import Expo signifies a collaborative approach to sustainability within the industry [6] Group 5: Lessons for the Industry - Haier Biomedical's ESG practices provide a replicable model for Chinese listed companies, emphasizing the integration of technological innovation with business growth [7] - The company's journey illustrates that ESG is not merely a reporting obligation but a fundamental aspect of operational strategy and product development [7] - The deep integration of ESG into business operations positions Haier Biomedical favorably in attracting long-term investors in the capital market [7]

Group 1: Haier Biomedical - Haier Biomedical showcased multiple technological products and digital solutions aimed at addressing practical needs in research and laboratory settings, including a super-speed centrifuge that achieves speeds of 100,000 RPM, filling a domestic gap in the field [2] - The company introduced a fully enclosed automated cell expansion system that enhances consistency and reproducibility in experiments by automating the cell culture process and ensuring data traceability [2] - Haier's biological sample management solution utilizes NAIT recognition technology for automated management in ultra-low temperature environments, significantly reducing labor costs and improving data accuracy [2] - The company presented energy-efficient products, such as ultra-low temperature storage boxes, which reportedly consume 50% less electricity than traditional models [2][3] - Haier Biomedical's products and solutions are now available in over 160 countries and regions, with a commitment to advancing technology development based on user challenges in real-world applications [3] Group 2: Medtronic - Medtronic announced the full localization of its product line in China, showcasing its "fully localized innovative solutions" at the expo, which includes core products for tumor treatment [5] - The company highlighted its Leksell Gamma Knife Elekta Esprit, which supports millimeter-level precision in radiation therapy, and the Elekta Evo platform that integrates AI imaging technology to enhance operational efficiency [5][6] - Medtronic's Elekta Unity system has treated over 10,000 patients since its introduction in China, covering more than 40 types of tumors and generating over 160 related clinical research papers [5][7] - The company aims to support China's "Healthy China 2030" initiative by promoting high-quality radiation therapy technology [7] Group 3: Fosun Pharma - Fosun Pharma presented various innovative drugs and high-end medical devices at the expo, focusing on improving treatment outcomes and quality of life for patients with diseases such as tumors and neurological disorders [8] - The company introduced the Da Vinci surgical robot and CAR-T cell therapy product Yikaida, which has been included in over 110 health insurance plans, enhancing accessibility for lymphoma patients [9] - Fosun's Marie particle therapy system, approved by the FDA, offers a compact design for rapid deployment in hospitals, improving treatment precision for lung and breast tumors [8][9] - The company is actively promoting the application of artificial intelligence in healthcare, with platforms designed for drug decision-making and clinical trial predictions [10]

Core Viewpoint - Haier Biomedical is leading the green transformation in the life sciences industry by launching innovative technologies and establishing a collaborative ecosystem for sustainable development [1][5]. Group 1: Technological Innovation - Haier Biomedical has established a foundation of green and technological advancement since 2005, breaking a 30-year foreign monopoly with the development of China's first ultra-low temperature storage box [2]. - The newly launched Eco-Drive ultra-green technology improves energy efficiency by 30% compared to the highest current industry standards, achieving the top rank in global energy efficiency [2]. - The AI-driven temperature and humidity control system for drug stability has increased energy efficiency by 80%, saving nearly 40,000 yuan in electricity costs annually for ten devices [3]. Group 2: Industry Standards and Certifications - Haier Biomedical has received multiple certifications, including 44 Energy Star certifications and 116 energy-saving environmental protection certificates, showcasing its commitment to sustainability [4]. - The company has been recognized in the S&P Global "Sustainability Yearbook (China Edition)" for three consecutive years, highlighting its leadership in green practices within the biomedicine sector [4]. Group 3: Collaborative Ecosystem - The company has initiated a green ecological co-construction initiative in collaboration with authoritative organizations like Ernst & Young and UL, aiming to promote green standards and practices across the industry [5][6]. - Haier Biomedical's solar vaccine refrigerator solution serves over 45 million children annually in more than 80 countries along the Belt and Road, addressing vaccine storage challenges in regions with inadequate power supply [7]. Group 4: Global Market Performance - In the first three quarters of this year, Haier Biomedical's overseas market revenue reached 634 million yuan, reflecting a year-on-year growth of 20.18%, driven by its green technology [7].